试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
编号:NCT03592641登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Savolitinib
登记的停止原因(原文):Inadequate accrual rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
编号:NCT03949673登记状态:提前终止企业 / 申办者:Regeneron Pharmaceuticals
药物 / 成分:Fasinumab、Naproxen、Diclofenac、Celecoxib
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
编号:NCT04404140登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Ipatasertib、Atezolizumab、Docetaxel
登记的停止原因(原文):Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab and docetaxel was challenging due to multiple study treatment modifications required to manage toxicity, making further enrollment inappropriate.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
编号:NCT04783389登记状态:提前终止企业 / 申办者:Connect Biopharm LLC
药物 / 成分:CBP-201、Placebo
登记的停止原因(原文):Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
Tricaprilin Liquid Formulation PK Study
编号:NCT05028114登记状态:提前终止企业 / 申办者:Cerecin
药物 / 成分:AC-1202、AC-OLE-01、AC-OLE-02、AC-OLE-03
登记的停止原因(原文):Part 1 was completed, Part 2 and Part 3 of the study were not conducted under this study protocol due to subject recruitment difficulty.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-16
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
编号:NCT03722108登记状态:提前终止企业 / 申办者:UNICANCER
药物 / 成分:Regorafenib and Irinotecan、Irinotecan
登记的停止原因(原文):Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate efficacy and safety analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-16
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
编号:NCT04607148登记状态:提前终止企业 / 申办者:Genentech, Inc.
药物 / 成分:Galegenimab
登记的停止原因(原文):The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-16
Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals
编号:NCT05788185登记状态:提前终止企业 / 申办者:RVAC Medicines (US), Inc.
药物 / 成分:RVM-V001 30 µg、RVM-V002 30 µg、RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration、RVM-V001 30 µg
登记的停止原因(原文):Changes in COVID-19 pandemic landscape
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
编号:NCT01891981登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Moxetumomab Pasudotox
登记的停止原因(原文):Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)
编号:NCT02608411登记状态:提前终止企业 / 申办者:Istituto Oncologico Veneto IRCCS
药物 / 成分:ARQ197
登记的停止原因(原文):Safety results (applied in METIV-HCC trial) have led early termination
查看官方原始记录 ↗